Generation of mycobacterial lipoarabinomannan-specific monoclonal antibodies and their ability to identify mycobacterium isolatesZhuohong Yan, Hongtao Zhang, Yu Pang et al.|Journal of Microbiology Immunology and Infection|2020Cited by 27
Lerociclib plus fulvestrant in patients with HR+/HER2− locally advanced or metastatic breast cancer who have progressed on prior endocrine therapy: LEONARDA-1 a phase III randomized trialTong Li, Bing Zhao, Shusen Wang et al.|Nature Communications|2025Cited by 10
LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy.Binghe Xu, Qingyuan Zhang, Yang Luo et al.|Journal of Clinical Oncology|2023Cited by 4
LBA25 Culmerciclib plus fulvestrant as first-line treatment for HR+/HER2- advanced breast cancer: A phase III trial (CULMINATE-2)Erwei Song, Fan Feng, Yue Yin et al.|Annals of Oncology|2025Cited by 2
495P Safety and efficacy of nab-sirolimus (HB1901) + endocrine therapy in HR+/HER2- advanced breast cancer after standard therapy failure: A multicenter, open-label, phase 2 studyFei Ma, Hongnan Mo, Jie Cui et al.|Annals of Oncology|2025Cited by 0